Latest & greatest articles for epilepsy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on epilepsy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on epilepsy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for epilepsy

81. Effectiveness of perioperative antiepileptic drug prophylaxis for early and late seizures following oncologic neurosurgery: a meta-analysis Full Text available with Trip Pro

Effectiveness of perioperative antiepileptic drug prophylaxis for early and late seizures following oncologic neurosurgery: a meta-analysis OBJECTIVEThe purpose of this meta-analysis was to evaluate the impact of perioperative antiepileptic drug (AED) prophylaxis on short- and long-term seizure incidence among patients undergoing brain tumor surgery. It is the first meta-analysis to focus exclusively on perioperative AED prophylaxis among patients undergoing brain tumor surgery.METHODSThe (...) authors searched PubMed/MEDLINE, Embase, Cochrane Central Register of Controlled Trials, clinicaltrials.gov, and the System for Information on Gray Literature in Europe for records related to perioperative AED prophylaxis for patients with brain tumors. Risk of bias in the included studies was assessed using the Cochrane risk of bias tool. Incidence rates for early seizures (within the first postoperative week) and total seizures were estimated based on data from randomized controlled trials. A Mantel

2018 EvidenceUpdates

82. Practice Guideline Update Summary: Efficacy and Tolerability of the New Antiepileptic Drugs I: Treatment of New-onset Epilepsy

as monotherapy, and how does their efficacy and tolerability compare with those of older antiepileptic drugs (AEDs)? • Clobazam (CLB) • Lacosamide • Perampanel • Topiramate (TPM) • Eslicarbazepine • Lamotrigine (LTG) • Pregabalin (PGB) • Vigabatrin (VGB • Felbamate (FBM) • Levetiracetam (LEV) • Rufinamide • Zonisamide (ZNS) • Gabapentin (GBP) • Oxcarbazepine (OXC) • Tiagabine Recommendations for monotherapy in adults with new-onset epilepsy with focal epilepsy or unclassified tonic-clonic seizures Level (...) profile precludes VGB use as first-line therapy. Level C PGB use at 150 mg/d is possibly less efficacious than LTG use at 100 mg/d. Level U Evidence is insufficient to consider GBP , OXC, or TPM instead of CBZ. Level U Evidence is insufficient to consider TPM instead of phenytoin in urgent treatment of new-onset or recurrent focal epilepsy, unclassified generalized tonic-clonic (GTC) seizures, or generalized epilepsy (GE) presenting with GTC seizures. Level U Data are lacking to support or refute use

2018 American Academy of Neurology

83. Practice Guideline Update Summary: Efficacy and Tolerability of the New Antiepileptic Drugs II: Treatment-resistant Epilepsy

the seizures of most patients with idiopathic GE are easily controlled with appropriate medication, presentation of TR epilepsy is rare. It is unclear how results in this population would translate to patients with similar syndromes but with nonrefractory disease. For adult and pediatric patients with Lennox-Gastaut syndrome (LGS), are these AEDs effective as adjunctive therapy in reducing seizure frequency (compared with no adjunctive therapy)? Level Recommendation Levels A and B For LGS, RFN use should (...) ) effective as adjunctive therapy in reducing seizure frequency? Level Recommendation* Level A For treatment-resistant adult focal epilepsy (TRAFE), immediate-release pregabalin (PGB) and perampanel (PER) are established as effective to reduce seizure frequency. Level B Lacosamide (LCM), eslicarbazepine (ESL), and extended-release topiramate use should also be considered to decrease seizure frequency in this population. Level A Vigabatrin (VGB) and rufinamide (RFN) should be considered established

2018 American Academy of Neurology

84. Antiepileptic drugs as prophylaxis for postcraniotomy seizures. Full Text available with Trip Pro

Antiepileptic drugs as prophylaxis for postcraniotomy seizures. This is an updated version of the Cochrane Review previously published in Issue 3, 2015.The incidence of seizures following supratentorial craniotomy for non-traumatic pathology has been estimated to be between 15% to 20%; however, the risk of experiencing a seizure appears to vary from 3% to 92% over a five-year period. Postoperative seizures can precipitate the development of epilepsy; seizures are most likely to occur within (...) the first month of cranial surgery. The use of antiepileptic drugs (AEDs) administered pre- or postoperatively to prevent seizures following cranial surgery has been investigated in a number of randomised controlled trials (RCTs).To determine the efficacy and safety of AEDs when used prophylactically in people undergoing craniotomy and to examine which AEDs are most effective.For the latest update we searched the following databases on 26 June 2017: Cochrane Epilepsy Group Specialized Register

2018 Cochrane

85. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. Full Text available with Trip Pro

Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. Cannabidiol has been used for treatment-resistant seizures in patients with severe early-onset epilepsy. We investigated the efficacy and safety of cannabidiol added to a regimen of conventional antiepileptic medication to treat drop seizures in patients with the Lennox-Gastaut syndrome, a severe developmental epileptic encephalopathy.In this double-blind, placebo-controlled trial conducted at 30 clinical centers, we (...) randomly assigned patients with the Lennox-Gastaut syndrome (age range, 2 to 55 years) who had had two or more drop seizures per week during a 28-day baseline period to receive cannabidiol oral solution at a dose of either 20 mg per kilogram of body weight (20-mg cannabidiol group) or 10 mg per kilogram (10-mg cannabidiol group) or matching placebo, administered in two equally divided doses daily for 14 weeks. The primary outcome was the percentage change from baseline in the frequency of drop seizures

2018 NEJM Controlled trial quality: predicted high

86. Incorporating epilepsy genetics into clinical practice: a 360°evaluation Full Text available with Trip Pro

for counseling and testing. We developed NGS panels, performing clinical interpretation with a multidisciplinary team. We held an educational workshop for paediatricians and nurses. We sent questionnaires to referring paediatricians and families. We analysed investigation costs for 16 neonatal epilepsy patients. Of 96 patients, a genetic diagnosis was made in 34% of patients with seizure onset < 2 years, and 4% > 2 years, with turnaround time of 21 days. Pathogenic variants were seen in SCN8A, SCN2A, SCN1A (...) Incorporating epilepsy genetics into clinical practice: a 360°evaluation We evaluated a new epilepsy genetic diagnostic and counseling service covering a UK population of 3.5 million. We calculated diagnostic yield, estimated clinical impact, and surveyed referring clinicians and families. We costed alternative investigational pathways for neonatal onset epilepsy. Patients with epilepsy of unknown aetiology onset < 2 years; treatment resistant epilepsy; or familial epilepsy were referred

2018 NPJ genomic medicine

87. Stiripentol add-on therapy for focal refractory epilepsy. Full Text available with Trip Pro

Stiripentol add-on therapy for focal refractory epilepsy. This is an updated version of the Cochrane review last published in 2015 (Issue 10). For nearly 30% of people with epilepsy, seizures are not controlled by current treatments. Stiripentol is a new antiepileptic drug (AED) that was developed in France and was approved by the European Medicines Agency (EMA) in 2007 for the treatment of Dravet syndrome as an adjunctive therapy with valproate and clobazam, with promising effects.To evaluate (...) -on trials of stiripentol in people with focal refractory epilepsy.Review authors independently selected trials for inclusion and extracted data. Outcomes investigated included 50% or greater reduction in seizure frequency, seizure freedom, adverse effects, treatment withdrawal and changes in quality of life.On the basis of our selection criteria, we included no new studies in the present review. Only one study was included from the earlier review (32 children with focal epilepsy). This study adopted

2018 Cochrane

88. Exploring the perception of women with epilepsy about pregnancy concerns: a qualitative study Full Text available with Trip Pro

Exploring the perception of women with epilepsy about pregnancy concerns: a qualitative study Epilepsy is a common neurological disorder in pregnancy, which is associated with increased maternal and fetal adverse outcomes. This study aimed to explore the reproductive healthcare needs of women with epilepsy before, during and after childbirth.This was a qualitative study using a content analysis method. The study population was marital women with epilepsy in reproductive age (15-45 years (...) for women with epilepsy, (2) doubt about the advantages and disadvantages of breastfeeding, (3) stigma as a block to the treatment of the postpartum depression, and (4) playing the motherhood role under the shadow of self-esteem to lack of self-esteem.In the prenatal, natal and postnatal duration, because of supportive system disruption and not receiving proper consultation, participants were often worried about not being able to get favorable conditions for safe pregnancy and controlling process

2018 Electronic physician

89. Clonazepam add-on therapy for refractory epilepsy in adults and children. Full Text available with Trip Pro

Clonazepam add-on therapy for refractory epilepsy in adults and children. Epilepsy affects about 50 million people worldwide, nearly a quarter of whom have drug-refractory epilepsy. People with drug-refractory epilepsy have increased risks of premature death, injuries, psychosocial dysfunction, and a reduced quality of life.To assess the efficacy and tolerability of clonazepam when used as an add-on therapy for adults and children with refractory focal onset or generalised onset epileptic (...) seizures, when compared with placebo or another antiepileptic agent.We searched the following databases on 14 September 2017: Cochrane Epilepsy Group Specialized Register, Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO), MEDLINE (Ovid 1946 to 14 September 2017), ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform (ICTRP).Double-blind randomised controlled studies of add-on clonazepam in people with refractory focal

2018 Cochrane

90. Epilepsy in Children After Pandemic Influenza Vaccination Full Text available with Trip Pro

Epilepsy in Children After Pandemic Influenza Vaccination To determine if pandemic influenza vaccination was associated with an increased risk of epilepsy in children.Information from Norwegian registries from 2006 through 2014 on all children <18 years living in Norway on October 1, 2009 was used in Cox regression models to estimate hazard ratios for incident epilepsy after vaccination. A self-controlled case series analysis was used to estimate incidence rate ratios in defined risk periods (...) after pandemic vaccination.In Norway, the main period of the influenza A subtype H1N1 pandemic was from October 2009 to December 2009. On October 1, 2009, 1 154 113 children <18 years of age were registered as residents in Norway. Of these, 572 875 (50.7%) were vaccinated against pandemic influenza. From October 2009 through 2014 there were 3628 new cases of epilepsy (incidence rate 6.09 per 10 000 person-years). The risk of epilepsy was not increased after vaccination: hazard ratio: 1.07; 95

2018 EvidenceUpdates

91. Rufinamide add-on therapy for refractory epilepsy. Full Text available with Trip Pro

Rufinamide add-on therapy for refractory epilepsy. Epilepsy is a central nervous system disorder (neurological disorder). Epileptic seizures are the result of excessive and abnormal cortical nerve cell electrical activity in the brain. Despite the development of more than 10 new antiepileptic drugs (AEDs) since the early 2000s, approximately a third of people with epilepsy remain resistant to pharmacotherapy, often requiring treatment with a combination of AEDs. In this review, we summarised (...) the current evidence regarding rufinamide, a novel anticonvulsant medication, which, as a triazole derivative, is structurally unrelated to any other currently used anticonvulsant medication, when used as an add-on treatment for refractory epilepsy. In January 2009, rufinamide was approved by the US Food and Drug Administration for treatment of children four years of age and older with Lennox-Gastaut syndrome. It is also approved as an add-on treatment for adults and adolescents with focal seizures.To

2018 Cochrane

92. Epilepsy, antiepileptic drugs, and serious transport accidents: A nationwide cohort study Full Text available with Trip Pro

used Cox regression to analyze the risk of serious transport accidents between individuals with epilepsy and matched controls, and then stratified Cox regression to compare the risk during periods of medication with the risk during nonmedication period within the same individual with epilepsy. We adjusted for civil status, employment, education, living area, psychiatric disorders prior to the start of follow-up, and psychotropic medication.Compared to matched controls, individuals with epilepsy (...) Epilepsy, antiepileptic drugs, and serious transport accidents: A nationwide cohort study To investigate the association between epilepsy and antiepileptic drugs and serious transport accidents requiring emergency care or resulting in death.We identified 29,220 individuals 18 years or older with epilepsy without cerebral palsy or intellectual disability and 267,637 matched controls using Swedish registers. This nationwide cohort was followed from 2006 to 2013 for serious transport accidents. We

2018 EvidenceUpdates

93. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence Full Text available with Trip Pro

% (95% CI 3.8% to 14.5%) were seizure-free. Twelve observational studies reported improved QoL (55.8%, 95% CI 40.5 to 70.6); 50.6% (95% CI 31.7 to 69.4) AEs and 2.2% (95% CI 0 to 7.9) SAEs. Pharmaceutical-grade CBD as adjuvant treatment in paediatric-onset drug-resistant epilepsy may reduce seizure frequency. Existing RCT evidence is mostly in paediatric samples with rare and severe epilepsy syndromes; RCTs examining other syndromes and cannabinoids are needed.CRD42017055412.© Article author(s (...) Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence Review evidence for cannabinoids as adjunctive treatments for treatment-resistant epilepsy. Systematic search of Medline, Embase and PsycINFO was conducted in October 2017. Outcomes were: 50%+ seizure reduction, complete seizure freedom; improved quality of life (QoL). Tolerability/safety were assessed by study withdrawals, adverse events (AEs) and serious adverse events (SAEs

2018 EvidenceUpdates

94. Cardiac arrhythmia and neuroexcitability gene variants in resected brain tissue from patients with sudden unexpected death in epilepsy (SUDEP) Full Text available with Trip Pro

Cardiac arrhythmia and neuroexcitability gene variants in resected brain tissue from patients with sudden unexpected death in epilepsy (SUDEP) Sudden unexpected death in epilepsy (SUDEP) is the leading cause of epilepsy-related mortality in young adults. The exact mechanisms are unknown but death often follows a generalized tonic-clonic seizure. Proposed mechanisms include seizure-related respiratory, cardiac, autonomic, and arousal dysfunction. Genetic drivers underlying SUDEP risk are largely (...) identified mutually exclusive variants in genes involved in µ-opiod signaling, gamma-aminobutyric acid (GABA) and glutamate-mediated synaptic signaling, including ARRB2, ITPR1, GABRR2, SSTR5, GRIK1, CTNAP2, GRM8, GNAI2 and GRIK5. In SUDEP patients we also identified variants in genes associated with cardiac arrhythmia, including KCNMB1, KCNIP1, DPP6, JUP, F2, and TUBA3D, which were not present in living epilepsy controls. Our data shows that genomic analysis of brain tissue resected for seizure control

2018 NPJ genomic medicine

95. Variant Intestinal-Cell Kinase in Juvenile Myoclonic Epilepsy. Full Text available with Trip Pro

in mice lacking a copy of Ick.A variant, K305T (c.914A→C), cosegregated with epilepsy or polyspikes on EEG in 12 members of the family affected with juvenile myoclonic epilepsy. We identified 21 pathogenic ICK variants in 22 of 310 additional patients (7%). Four strongly linked variants (K220E, K305T, A615T, and R632X) impaired mitosis, cell-cycle exit, and radial neuroblast migration while promoting apoptosis. Tonic-clonic convulsions and polyspikes on EEG resembling seizures in human juvenile (...) Variant Intestinal-Cell Kinase in Juvenile Myoclonic Epilepsy. In juvenile myoclonic epilepsy, data are limited on the genetic basis of networks promoting convulsions with diffuse polyspikes on electroencephalography (EEG) and the subtle microscopic brain dysplasia called microdysgenesis.Using Sanger sequencing, we sequenced the exomes of six members of a large family affected with juvenile myoclonic epilepsy and confirmed cosegregation in all 37 family members. We screened an additional 310

2018 NEJM

96. Lacosamide (Vimpat) - partial-onset seizures

Lacosamide (Vimpat) - partial-onset seizures Published 12 March 2018 Statement of Advice: lacosamide, 50mg, 100mg, 150mg, 200mg tablets, 10mg/mL syrup and 10mg/mL solution for intravenous infusion (Vimpat ® ) SMC No 1324/18 UCB Pharma Limited 9 February 2018 ADVICE: in the absence of a submission from the holder of the marketing authorisation lacosamide (Vimpat ® ) is not recommended for use within NHS Scotland. Indication under review: As monotherapy in the treatment of partial-onset seizures (...) with or without secondary generalisation in adolescents and children from 4 years of age with epilepsy. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug

2018 Scottish Medicines Consortium

97. Lacosamide (Vimpat) - treatment of partial-onset seizures with or without secondary generalisation in children

Lacosamide (Vimpat ® ) is recommended as an option for use within NHS Wales as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in children from = 4 years of age to = 15 years of age with epilepsy. Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: All Wales Medicines Strategy Group Final Appraisal Recommendation – 0318: Lacosamide (Vimpat ® ) 50 mg, 100 mg, 150 mg (...) Lacosamide (Vimpat) - treatment of partial-onset seizures with or without secondary generalisation in children Final Appraisal Recommendation Advice No: 0318 – Feb 2018 Lacosamide (Vimpat ® ) 50 mg, 100 mg, 150 mg, 200 mg film-coated tablets; 10 mg/ml syrup; 10 mg/ml solution for infusion Limited submission by UCB Pharma Ltd. Additional note(s): • Please refer to the Summary of Product Characteristics for the full licensed indication. In reaching the above recommendation AWMSG has taken account

2018 All Wales Medicines Strategy Group

98. Attention-deficit/hyperactivity disorder medication and seizures Full Text available with Trip Pro

Attention-deficit/hyperactivity disorder medication and seizures Individuals with attention-deficit/hyperactivity disorder (ADHD) are at increased risk of seizures, but there is uncertainty about whether ADHD medication treatment increases risk among patients with and without preexisting seizures.We followed a sample of 801,838 patients with ADHD who had prescribed drug claims from the Truven Health MarketScan Commercial Claims and Encounters databases to examine whether ADHD medication (...) increases the likelihood of seizures among ADHD patients with and without a history of seizures. First, we assessed overall risk of seizures among patients with ADHD. Second, within-individual concurrent analyses assessed odds of seizure events during months when a patient with ADHD received ADHD medication compared with when the same individual did not, while adjusting for antiepileptic medications. Third, within-individual long-term analyses examined odds of seizure events in relation to the duration

2018 EvidenceUpdates

99. Behavioral interventions as a treatment for epilepsy: A multicenter randomized controlled trial (Abstract)

Behavioral interventions as a treatment for epilepsy: A multicenter randomized controlled trial To evaluate the effect of a stress-reduction intervention in participants with medication-resistant epilepsy.Adults with medication-resistant focal epilepsy (n = 66) were recruited from 3 centers and randomized to 1 of 2 interventions: (1) progressive muscle relaxation (PMR) with diaphragmatic breathing, or (2) control focused-attention activity with extremity movements. Following an 8-week baseline (...) period, participants began 12 weeks of double-blind treatment. Daily self-reported mood and stress ratings plus seizure counts were completed by participants using an electronic diary, and no medication adjustments were permitted. The primary outcome was percent reduction in seizure frequency per 28 days comparing baseline and treatment; secondary outcomes included stress reduction and stress-seizure interaction.In the 66 participants in the intention-to-treat analysis, seizure frequency was reduced

2018 EvidenceUpdates

100. Care delivery and self-management strategies for children with epilepsy. Full Text available with Trip Pro

Care delivery and self-management strategies for children with epilepsy. In response to criticism that epilepsy care for children has little impact, healthcare professionals and administrators have developed various service models and strategies to address perceived inadequacies.To assess the effects of any specialised or dedicated intervention for epilepsy versus usual care in children with epilepsy and in their families.We searched the Cochrane Epilepsy Group Specialized Register (27 (...) September 2016), the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 9) in the Cochrane Library, MEDLINE (1946 to 27 September 2016), Embase (1974 to 27 September 2016), PsycINFO (1887 to 27 September 2016) and CINAHL Plus (1937 to 27 September 2016). In addition, we also searched clinical trials registries for ongoing or recently completed trials, contacted experts in the field to seek information on unpublished and ongoing studies, checked the websites of epilepsy organisations

2018 Cochrane